Efficacy of daily compared to intermittent administration of IL-1Ra for protection against bone and cartilage destruction in collagen-challenged mice
- PMID: 12673887
Efficacy of daily compared to intermittent administration of IL-1Ra for protection against bone and cartilage destruction in collagen-challenged mice
Abstract
Objective: To investigate the protective effect of interleukin-1 receptor antagonist (IL-1Ra) on bone and cartilage destruction in the induction phase of collagen-induced arthritis (CIA), an animal model of rheumatoid arthritis (RA).
Methods: DBA/1J mice were immunized with type II collagen for induction of collagen-induced arthritis (CIA) and simultaneously given different intraperitoneal doses of IL-1Ra daily, thrice weekly or once a week. Clinical symptoms of arthritis were noted daily and assessed using a scoring system during the course of disease. Bone and cartilage destruction in the mice was assessed by radiographic and histological methods respectively.
Results: Mice injected with IL-1Ra daily were completely protected from the occurrence of arthritis after immunization with type II collagen. Moreover, these mice were also protected against bone and cartilage destruction. However, weekly or thrice weekly treatment with IL-1Ra had no effect on arthritis and bone and cartilage destruction.
Conclusion: Daily administration of recombinant IL-1Ra, injected at the same time as arthritis induction, is effective in blocking the occurrence of inflammatory as well as destructive changes in CIA. Daily bolus injections of IL-1Ra may therefore be useful for protection against joint damage following minor joint injury, whereas the maintenance of appropriate blood levels of the antagonist may be critical for its therapeutic effect on chronic inflammatory arthritis.
Similar articles
-
Protection against cartilage and bone destruction by systemic interleukin-4 treatment in established murine type II collagen-induced arthritis.Arthritis Res. 1999;1(1):81-91. doi: 10.1186/ar14. Epub 1999 Oct 26. Arthritis Res. 1999. PMID: 11056663 Free PMC article.
-
IL-1 alpha beta blockade prevents cartilage and bone destruction in murine type II collagen-induced arthritis, whereas TNF-alpha blockade only ameliorates joint inflammation.J Immunol. 1999 Nov 1;163(9):5049-55. J Immunol. 1999. PMID: 10528210
-
Efficacy of sustained blood levels of interleukin-1 receptor antagonist in animal models of arthritis: comparison of efficacy in animal models with human clinical data.Arthritis Rheum. 1999 Mar;42(3):498-506. doi: 10.1002/1529-0131(199904)42:3<498::AID-ANR15>3.0.CO;2-A. Arthritis Rheum. 1999. PMID: 10088773 Clinical Trial.
-
Blocking the effects of IL-1 in rheumatoid arthritis protects bone and cartilage.Rheumatology (Oxford). 2002 Sep;41(9):972-80. doi: 10.1093/rheumatology/41.9.972. Rheumatology (Oxford). 2002. PMID: 12209029 Review.
-
Gene therapy for rheumatoid arthritis. Lessons from animal models, including studies on interleukin-4, interleukin-10, and interleukin-1 receptor antagonist as potential disease modulators.Rheum Dis Clin North Am. 2002 Feb;28(1):127-49. doi: 10.1016/s0889-857x(03)00073-5. Rheum Dis Clin North Am. 2002. PMID: 11840694 Review.
Cited by
-
Synthesis of self-assembled IL-1Ra-presenting nanoparticles for the treatment of osteoarthritis.J Biomed Mater Res A. 2016 Mar;104(3):595-599. doi: 10.1002/jbm.a.35601. Epub 2015 Nov 9. J Biomed Mater Res A. 2016. PMID: 26507256 Free PMC article.
-
Effects of interleukin-1 receptor antagonist on tumor stroma in experimental uveal melanoma.Invest Ophthalmol Vis Sci. 2011 Jul 25;52(8):5529-35. doi: 10.1167/iovs.10-6331. Invest Ophthalmol Vis Sci. 2011. PMID: 21519029 Free PMC article.
-
Targeting pro-inflammatory cytokines following joint injury: acute intra-articular inhibition of interleukin-1 following knee injury prevents post-traumatic arthritis.Arthritis Res Ther. 2014 Jun 25;16(3):R134. doi: 10.1186/ar4591. Arthritis Res Ther. 2014. PMID: 24964765 Free PMC article.
-
Chitosan/hyaluronic acid/plasmid-DNA nanoparticles encoding interleukin-1 receptor antagonist attenuate inflammation in synoviocytes induced by interleukin-1 beta.J Mater Sci Mater Med. 2018 Oct 1;29(10):155. doi: 10.1007/s10856-018-6160-3. J Mater Sci Mater Med. 2018. PMID: 30276528 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources